RU2011149796A - HIGHER DEVELOPMENT MEDICINAL COMPOSITIONS BASED ON PEPTIDES AND RELATED COMPOUNDS PEPTIDES - Google Patents
HIGHER DEVELOPMENT MEDICINAL COMPOSITIONS BASED ON PEPTIDES AND RELATED COMPOUNDS PEPTIDES Download PDFInfo
- Publication number
- RU2011149796A RU2011149796A RU2011149796/02A RU2011149796A RU2011149796A RU 2011149796 A RU2011149796 A RU 2011149796A RU 2011149796/02 A RU2011149796/02 A RU 2011149796/02A RU 2011149796 A RU2011149796 A RU 2011149796A RU 2011149796 A RU2011149796 A RU 2011149796A
- Authority
- RU
- Russia
- Prior art keywords
- structures
- substituted
- unsubstituted
- group
- peptide
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 36
- 150000001875 compounds Chemical class 0.000 title claims 15
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 6
- 230000035515 penetration Effects 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 101700000977 CAD1 Proteins 0.000 claims 9
- 101700005869 DCLY Proteins 0.000 claims 9
- 125000003282 alkyl amino group Chemical group 0.000 claims 9
- 125000004414 alkyl thio group Chemical group 0.000 claims 9
- 101700083189 ldc Proteins 0.000 claims 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 150000001350 alkyl halides Chemical class 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- 229940088597 Hormone Drugs 0.000 claims 6
- 230000002159 abnormal effect Effects 0.000 claims 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 6
- 239000005556 hormone Substances 0.000 claims 6
- 239000011347 resin Substances 0.000 claims 6
- 229920005989 resin Polymers 0.000 claims 6
- 206010061218 Inflammation Diseases 0.000 claims 5
- 210000003491 Skin Anatomy 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 125000004432 carbon atoms Chemical group C* 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 5
- 230000004054 inflammatory process Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 229910052698 phosphorus Inorganic materials 0.000 claims 5
- 230000001225 therapeutic Effects 0.000 claims 5
- 230000032258 transport Effects 0.000 claims 5
- -1 2'-naphthyl Chemical group 0.000 claims 4
- 210000004369 Blood Anatomy 0.000 claims 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims 4
- 125000005647 linker group Chemical group 0.000 claims 4
- 239000002207 metabolite Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 206010012601 Diabetes mellitus Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 108010093625 Opioid Peptides Proteins 0.000 claims 3
- 102000001490 Opioid Peptides Human genes 0.000 claims 3
- 206010039710 Scleroderma Diseases 0.000 claims 3
- 206010043778 Thyroiditis Diseases 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 230000036772 blood pressure Effects 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 3
- 101700082223 how Proteins 0.000 claims 3
- 239000003399 opiate peptide Substances 0.000 claims 3
- 210000000056 organs Anatomy 0.000 claims 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims 3
- 101710004799 sm-amp-x Proteins 0.000 claims 3
- 238000001308 synthesis method Methods 0.000 claims 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 206010000496 Acne Diseases 0.000 claims 2
- 206010003816 Autoimmune disease Diseases 0.000 claims 2
- 108060001001 BRK1 Proteins 0.000 claims 2
- 208000003432 Bone Disease Diseases 0.000 claims 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N Bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 2
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 2
- 210000001072 Colon Anatomy 0.000 claims 2
- 102000002045 Endothelin Human genes 0.000 claims 2
- 108050009340 Endothelin Proteins 0.000 claims 2
- 208000009745 Eye Disease Diseases 0.000 claims 2
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N Gentisic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims 2
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 claims 2
- 208000002287 Hemorrhoids Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 102100011311 KNG1 Human genes 0.000 claims 2
- 210000004072 Lung Anatomy 0.000 claims 2
- 206010057672 Male sexual dysfunction Diseases 0.000 claims 2
- 208000008466 Metabolic Disease Diseases 0.000 claims 2
- 210000000214 Mouth Anatomy 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 101800001442 Peptide pr Proteins 0.000 claims 2
- 210000002307 Prostate Anatomy 0.000 claims 2
- 210000000664 Rectum Anatomy 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- JKEKMBGUVUKMQB-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JKEKMBGUVUKMQB-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000003042 antagnostic Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000001684 chronic Effects 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 230000004807 localization Effects 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- 244000005700 microbiome Species 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 150000002923 oximes Chemical class 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 2
- 108010016009 procolipase activation peptide Proteins 0.000 claims 2
- 201000007094 prostatitis Diseases 0.000 claims 2
- 230000001681 protective Effects 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 108010058394 valyl-prolyl-aspartyl-prolyl-arginine Proteins 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2S)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 claims 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 claims 1
- 101700015530 AGTR2 Proteins 0.000 claims 1
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 claims 1
- 229960000583 Acetic Acid Drugs 0.000 claims 1
- 206010000503 Acne cystic Diseases 0.000 claims 1
- 201000004304 Addison's disease Diseases 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 102000005862 Angiotensin II Human genes 0.000 claims 1
- 229950006323 Angiotensin ii Drugs 0.000 claims 1
- 101800000733 Angiotensin-2 Proteins 0.000 claims 1
- 108010064733 Angiotensins Proteins 0.000 claims 1
- 102000015427 Angiotensins Human genes 0.000 claims 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 1
- 210000001367 Arteries Anatomy 0.000 claims 1
- 206010003246 Arthritis Diseases 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010004053 Bacterial toxaemia Diseases 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 1
- 206010004950 Birth mark Diseases 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 208000001183 Brain Injury Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 102400000113 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- 229960004015 Calcitonin Drugs 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010011401 Crohn's disease Diseases 0.000 claims 1
- 208000004921 Cutaneous Lupus Erythematosus Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-N Disulfuric acid Chemical compound OS(=O)(=O)OS(O)(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-N 0.000 claims 1
- 210000001198 Duodenum Anatomy 0.000 claims 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N Endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
- 208000010305 Epidermal Cyst Diseases 0.000 claims 1
- 210000001508 Eye Anatomy 0.000 claims 1
- 229940012952 Fibrinogen Drugs 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 229940019698 Fibrinogen containing hemostatics Drugs 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 229960002598 Fumaric acid Drugs 0.000 claims 1
- 101700005903 GAST Proteins 0.000 claims 1
- 102100001448 GAST Human genes 0.000 claims 1
- 102100003313 GHRL Human genes 0.000 claims 1
- 101700054787 GHRP Proteins 0.000 claims 1
- 210000000232 Gallbladder Anatomy 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 210000004392 Genitalia Anatomy 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 229940097043 Glucuronic Acid Drugs 0.000 claims 1
- 229960002989 Glutamic Acid Drugs 0.000 claims 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N Gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims 1
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 claims 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims 1
- 206010056438 Growth hormone deficiency Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 206010065057 Haemophilic arthropathy Diseases 0.000 claims 1
- 210000002216 Heart Anatomy 0.000 claims 1
- 206010020649 Hyperkeratosis Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 208000003532 Hypothyroidism Diseases 0.000 claims 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II dizwitterion Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 1
- 206010022437 Insomnia Diseases 0.000 claims 1
- 210000000936 Intestines Anatomy 0.000 claims 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-N Isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 claims 1
- 208000001126 Keratosis Diseases 0.000 claims 1
- 210000003734 Kidney Anatomy 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 229960000448 Lactic acid Drugs 0.000 claims 1
- 102000007547 Laminin Human genes 0.000 claims 1
- 108010085895 Laminin Proteins 0.000 claims 1
- 108010022337 Leucine Enkephalin Proteins 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 241000208202 Linaceae Species 0.000 claims 1
- 235000004431 Linum usitatissimum Nutrition 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 210000002751 Lymph Anatomy 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 208000003393 Mammary Paget's Disease Diseases 0.000 claims 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 claims 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 claims 1
- 206010027145 Melanocytic naevus Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims 1
- 102400000988 Met-enkephalin Human genes 0.000 claims 1
- 230000035633 Metabolized Effects 0.000 claims 1
- 206010027452 Metastases to bone Diseases 0.000 claims 1
- 206010027476 Metastasis Diseases 0.000 claims 1
- YFGBQHOOROIVKG-FKBYEOEOSA-N Metenkefalin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-FKBYEOEOSA-N 0.000 claims 1
- 108010042237 Methionine Enkephalin Proteins 0.000 claims 1
- 208000001725 Mucocutaneous Lymph Node Syndrome Diseases 0.000 claims 1
- 208000010125 Myocardial Infarction Diseases 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 1
- 229910004013 NO 2 Inorganic materials 0.000 claims 1
- 102000003797 Neuropeptides Human genes 0.000 claims 1
- 108090000189 Neuropeptides Proteins 0.000 claims 1
- 208000007256 Nevus Diseases 0.000 claims 1
- 206010054107 Nodule Diseases 0.000 claims 1
- 210000001331 Nose Anatomy 0.000 claims 1
- 206010030043 Ocular hypertension Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 102100002857 PDYN Human genes 0.000 claims 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims 1
- 210000000496 Pancreas Anatomy 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 229940055726 Pantothenic Acid Drugs 0.000 claims 1
- 206010033733 Papule Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 206010034695 Pernicious anaemia Diseases 0.000 claims 1
- 206010057249 Phagocytosis Diseases 0.000 claims 1
- 102100011271 Phagocytosis-stimulating peptide Human genes 0.000 claims 1
- 208000005987 Polymyositis Diseases 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010051482 Prostatomegaly Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 208000005069 Pulmonary Fibrosis Diseases 0.000 claims 1
- 210000004915 Pus Anatomy 0.000 claims 1
- 206010037888 Rash pustular Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 206010040767 Sjogren's syndrome Diseases 0.000 claims 1
- 206010064127 Solar lentigo Diseases 0.000 claims 1
- 229960000553 Somatostatin Drugs 0.000 claims 1
- 102000005157 Somatostatin Human genes 0.000 claims 1
- 108010056088 Somatostatin Proteins 0.000 claims 1
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 claims 1
- 210000002784 Stomach Anatomy 0.000 claims 1
- 229960005137 Succinic Acid Drugs 0.000 claims 1
- 210000002105 Tongue Anatomy 0.000 claims 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N Triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 claims 1
- 108010084754 Tuftsin Proteins 0.000 claims 1
- IESDGNYHXIOKRW-LEOABGAYSA-N Tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 claims 1
- 229940035670 Tuftsin Drugs 0.000 claims 1
- 206010068760 Ulcers Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 210000004291 Uterus Anatomy 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 108010004977 Vasopressins Proteins 0.000 claims 1
- 102000002852 Vasopressins Human genes 0.000 claims 1
- 210000003462 Veins Anatomy 0.000 claims 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 1
- 208000000260 Warts Diseases 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- UQYZFNUUOSSNKT-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 UQYZFNUUOSSNKT-UHFFFAOYSA-N 0.000 claims 1
- 230000003023 adrenocorticotropic Effects 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 230000002686 anti-diuretic Effects 0.000 claims 1
- 230000003048 anti-oxytocin Effects 0.000 claims 1
- 230000000890 antigenic Effects 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 201000004569 blindness Diseases 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims 1
- 230000004094 calcium homeostasis Effects 0.000 claims 1
- 229960002079 calcium pantothenate Drugs 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 201000011529 cardiovascular cancer Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 229960004106 citric acid Drugs 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 239000007822 coupling agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 229960005219 gentisic acid Drugs 0.000 claims 1
- 239000000174 gluconic acid Substances 0.000 claims 1
- 229950006191 gluconic acid Drugs 0.000 claims 1
- 235000012208 gluconic acid Nutrition 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000002989 hypothyroidism Effects 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 150000002466 imines Chemical class 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000010410 layer Substances 0.000 claims 1
- 230000003902 lesions Effects 0.000 claims 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 231100000864 loss of vision Toxicity 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 229940098895 maleic acid Drugs 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000002865 melanocortin Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000009245 menopause Effects 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000011713 pantothenic acid Substances 0.000 claims 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N pantothenic acid Natural products OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims 1
- 235000019161 pantothenic acid Nutrition 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000037025 penetration rate Effects 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 230000002093 peripheral Effects 0.000 claims 1
- 230000008782 phagocytosis Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 108010070701 procolipase Proteins 0.000 claims 1
- 230000002062 proliferating Effects 0.000 claims 1
- 201000004883 prostatocystitis Diseases 0.000 claims 1
- 239000011241 protective layer Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000005588 protonation Effects 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 230000001185 psoriatic Effects 0.000 claims 1
- 230000002685 pulmonary Effects 0.000 claims 1
- 239000003488 releasing hormone Substances 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims 1
- 231100000486 side effect Toxicity 0.000 claims 1
- 201000010153 skin papilloma Diseases 0.000 claims 1
- 238000010532 solid phase synthesis reaction Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 229960001367 tartaric acid Drugs 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 125000001302 tertiary amino group Chemical group 0.000 claims 1
- 150000007970 thio esters Chemical class 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 230000000699 topical Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 201000006704 ulcerative colitis Diseases 0.000 claims 1
- 230000002485 urinary Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000003966 vascular damage Effects 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N β-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 claims 1
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical class C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 claims 1
- YUQPGWMMVGQXOJ-UHFFFAOYSA-N CC(C)OC(C(CCSC)NC(C(Cc1ccccc1)NC(CNC(CNC(C(Cc(cc1)ccc1O)N)=O)=O)=O)=O)=O Chemical compound CC(C)OC(C(CCSC)NC(C(Cc1ccccc1)NC(CNC(CNC(C(Cc(cc1)ccc1O)N)=O)=O)=O)=O)=O YUQPGWMMVGQXOJ-UHFFFAOYSA-N 0.000 description 1
- USLRFXYLTMBJRT-UHFFFAOYSA-N CC(C)OC(C(CCSC)NC(C(Cc1ccccc1)NC(CNC(CNC(C(Cc(cc1)ccc1OC(C)=O)N)=O)=O)=O)=O)=O Chemical compound CC(C)OC(C(CCSC)NC(C(Cc1ccccc1)NC(CNC(CNC(C(Cc(cc1)ccc1OC(C)=O)N)=O)=O)=O)=O)=O USLRFXYLTMBJRT-UHFFFAOYSA-N 0.000 description 1
Claims (48)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910135997 | 2009-05-08 | ||
US12/463,374 US9376381B2 (en) | 2006-11-08 | 2009-05-08 | High penetration prodrug compositions of peptides and peptide-related compounds |
US12/463,374 | 2009-05-08 | ||
CN200910135997.0 | 2009-05-08 | ||
PCT/CN2010/072561 WO2010127640A1 (en) | 2009-05-08 | 2010-05-10 | High penetration prodrug compositions of peptides and peptide-related compounds |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016139056A Division RU2767051C2 (en) | 2009-05-08 | 2010-05-10 | High-penetration prodrug compositions based on peptides and peptide-related compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2011149796A true RU2011149796A (en) | 2013-06-20 |
RU2627065C2 RU2627065C2 (en) | 2017-08-03 |
Family
ID=43049997
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011149796A RU2627065C2 (en) | 2009-05-08 | 2010-05-10 | Prodrug compositions with high degree of penetration based on peptides and related compounds |
RU2016139056A RU2767051C2 (en) | 2009-05-08 | 2010-05-10 | High-penetration prodrug compositions based on peptides and peptide-related compounds |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016139056A RU2767051C2 (en) | 2009-05-08 | 2010-05-10 | High-penetration prodrug compositions based on peptides and peptide-related compounds |
Country Status (15)
Country | Link |
---|---|
US (1) | US9248109B2 (en) |
EP (3) | EP2660247A3 (en) |
JP (4) | JP6352587B2 (en) |
KR (3) | KR101784528B1 (en) |
CN (3) | CN108084246A (en) |
AU (2) | AU2010244857A1 (en) |
BR (1) | BRPI1011439B8 (en) |
CA (1) | CA2761489C (en) |
DK (1) | DK2427475T3 (en) |
ES (1) | ES2845612T3 (en) |
MX (2) | MX355995B (en) |
PL (1) | PL2427475T3 (en) |
RU (2) | RU2627065C2 (en) |
TW (1) | TWI568447B (en) |
WO (1) | WO2010127640A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1782819A1 (en) * | 2005-11-03 | 2007-05-09 | Cognis IP Management GmbH | Oligopeptides and their use |
CN108084246A (en) * | 2009-05-08 | 2018-05-29 | 上海泰飞尔生化技术有限公司 | The high penetrating power prodrugs composition of polypeptide and polypeptide related compound |
SG187271A1 (en) * | 2011-07-07 | 2013-02-28 | Agency Science Tech & Res | Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic |
JP2016516018A (en) * | 2013-03-15 | 2016-06-02 | テックフィールズ ファーマ カンパニー リミテッド | Novel high-permeability drug and its composition for treating Parkinson's disease |
EP3936141A3 (en) * | 2015-01-23 | 2022-03-23 | Erasmus University Rotterdam Medical Center | Anti-senescence compounds and uses thereof |
JP7011830B2 (en) | 2015-10-14 | 2022-01-27 | エックス-サーマ インコーポレイテッド | Compositions and Methods for Reducing Ice Crystal Formation |
WO2019059963A1 (en) * | 2017-09-21 | 2019-03-28 | Dignify Therapeutics, Llc | Compositions for inducing urinary voiding and defecation |
RU2674447C1 (en) * | 2017-12-19 | 2018-12-10 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Дальневосточный государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ДВГМУ Минздрава России) | Method for treatment of excess bacterial growth in small intestine in patients with type 2 diabetes in combination with gastroduodenal helicobacteriosis |
KR20230106616A (en) * | 2020-11-09 | 2023-07-13 | 엠바크 바이오테크 에이피에스 | Compounds and uses thereof in the treatment of tachykinin receptor mediated disorders |
CN112843222B (en) * | 2021-01-21 | 2023-01-31 | 暨南大学 | Application of ANKRD22 protein in preparing product for treating or delaying autoimmune diseases |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2542998B1 (en) | 1983-03-24 | 1986-01-31 | Rhone Poulenc Sante | NEW TRANSDERMAL FORM OF ISOSORBIDE DINITRATE |
US5556942A (en) | 1991-04-29 | 1996-09-17 | Terrapin Technologies, Inc. | Glutathione S-transferase-activated compounds |
ATE162725T1 (en) | 1991-10-16 | 1998-02-15 | Richardson Vicks Inc | IMPROVED SKIN PENETRATION SYSTEMS FOR INCREASED TOPICAL RELEASE OF DRUGS |
WO1997003939A1 (en) | 1995-07-21 | 1997-02-06 | Genta Incorporated | Novel amide-based cationic lipids |
EP0784984B1 (en) | 1996-01-17 | 2003-07-02 | F. Hoffmann-La Roche Ag | Transfection competent molecules |
EP0910571B1 (en) | 1996-05-03 | 2005-07-20 | Abbott Laboratories | Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis |
US6011049A (en) | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
KR20020008168A (en) | 1999-04-30 | 2002-01-29 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | ACE-2 Inhibiting Compounds and Methods of Use Thereof |
AU4841700A (en) | 1999-05-12 | 2000-11-21 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
US7671029B2 (en) * | 1999-08-06 | 2010-03-02 | Immupharma Sa | Compositions and methods for enhanced pharmacological activity of compositions comprising peptide drug substances |
US6669951B2 (en) * | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US6693135B2 (en) | 2000-01-10 | 2004-02-17 | Nexmed (Holdings) Incorporated | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
WO2002010195A2 (en) * | 2000-08-02 | 2002-02-07 | Theratechnologies Inc. | Modified peptides with increased potency |
US20040121947A1 (en) | 2000-12-28 | 2004-06-24 | Oklahoma Medical Research Foundation | Compounds which inhibit beta-secretase activity and methods of use thereof |
CN1545422B (en) * | 2001-01-17 | 2010-09-22 | 罗伯特·H·齐默尔 | Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingred |
WO2003022270A1 (en) | 2001-09-13 | 2003-03-20 | Noven Pharmaceuticals, Inc. | Transdermal administration of an enalapril ester |
JP2003267996A (en) * | 2002-03-14 | 2003-09-25 | Noguchi Inst | N-acetylglucosamine-bound opioid peptide derivative |
EP1569678A4 (en) | 2002-11-25 | 2008-01-02 | Attenuon Llc | Peptides which target tumor and endothelial cells, compositions and uses thereof |
AU2004220457A1 (en) | 2003-03-12 | 2004-09-23 | Celgene Corporation | 7-amino- isoindolyl compounds amd their pharmaceutical uses |
US7052715B2 (en) | 2003-04-11 | 2006-05-30 | All Natural Fmg, Inc. | Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof |
TW200538149A (en) | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
EP1605064A1 (en) | 2004-06-07 | 2005-12-14 | UMC Utrecht Holding B.V. | HIV Variant showing a novel resistance mechanism against protease inhibitors, diagnostic assays for detecting the variant, and methods for identifying drugs effective against the resistant virus |
US7074775B2 (en) * | 2004-09-14 | 2006-07-11 | Miller Landon C G | Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders |
SI1833978T1 (en) | 2005-01-06 | 2009-04-30 | Telik Inc | Tripeptide and tetrapeptide thioethers |
WO2007070563A2 (en) * | 2005-12-13 | 2007-06-21 | Harkness Pharmaceuticals, Inc. | Stable solid forms of enterostatin |
WO2007070562A2 (en) * | 2005-12-13 | 2007-06-21 | Harkness Pharmaceuticals, Inc. | Non-hygroscopic compositions of enterostatin |
EP1973953A2 (en) * | 2005-12-16 | 2008-10-01 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating obesity and related metabolic disorders |
WO2007128757A2 (en) * | 2006-05-02 | 2007-11-15 | Actogenix N.V. | Microbial intestinal delivery of obesity related peptides |
WO2008007171A1 (en) | 2006-07-09 | 2008-01-17 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of aspirin |
EP2043744A2 (en) * | 2006-07-13 | 2009-04-08 | SmithKline Beecham Corporation | Chemical compounds |
ES2616315T3 (en) | 2006-07-18 | 2017-06-12 | Techfields Biochem Co. Ltd | Water-soluble ibuprofen prodrugs positively charged with a very fast skin penetration rate |
CA2658712C (en) | 2006-07-25 | 2018-10-02 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of diclofenac with very fast skin penetration rate |
CN101500983B (en) | 2006-07-26 | 2015-09-16 | 于崇曦 | Positively charged water-soluble prodrugs of diflunisal and related compounds with fast skin penetration rate |
PT2049482E (en) | 2006-08-08 | 2016-02-24 | Techfields Biochem Co Ltd | Positively charged water-soluble prodrugs of aryl- and heteroarylacetic acids with very fast skin penetration rate |
US8458932B2 (en) | 2006-08-11 | 2013-06-11 | Alameda Technology, Llc | Optical illusion device |
JP5424880B2 (en) | 2006-08-15 | 2014-02-26 | テックフィールズ バイオケム カンパニー リミテッド | Positively charged water-soluble prodrugs of aryl- and heteroarylpropionic acids with very fast skin permeability |
WO2008026776A1 (en) | 2006-08-31 | 2008-03-06 | Nanocarrier Co., Ltd. | Transdermal composition, transdermal pharmaceutical composition and transdermal cosmetic composition comprising polymer micelle encapsulating active ingredient |
EP2084132B1 (en) | 2006-09-03 | 2018-08-08 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of n-arylanthranilic acids with very fast skin penetration rate |
EP2746251A3 (en) | 2006-09-03 | 2014-07-02 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of acetaminophen and related compunds with very fast skin penetration rate |
CN101522692A (en) | 2006-10-11 | 2009-09-02 | 于崇曦 | Positively charged water-soluble prodrugs of oxicams and related compounds with very high skin penetration rate |
CN101541743A (en) * | 2006-11-08 | 2009-09-23 | 于崇曦 | Transdermal delivery systems of peptides and related compounds |
JP5324463B2 (en) | 2006-12-10 | 2013-10-23 | チョンシー ユー | Transdermal delivery system for β-lactam antibiotics |
WO2008072023A1 (en) * | 2006-12-13 | 2008-06-19 | Otis Elevator Company | Portable emergency and inspection interface for elevators |
EP2125697B1 (en) * | 2007-01-15 | 2016-09-28 | Chongxi Yu | Positively charged water-soluble prodrugs of retinoids and retinoid-like compounds with very high skin penetration rates |
JP5389668B2 (en) | 2007-01-31 | 2014-01-15 | チョンシー ユー | Positively charged water-soluble prodrugs of 1H-imidazo [4,5-c] quinolin-4-amine and related compounds with very high skin permeability |
CN105820107B (en) | 2007-06-04 | 2022-09-09 | 泰飞尔公司 | Prodrug of non-steroidal anti-inflammatory drug with rapid skin and biological membrane penetration speed and novel medical application thereof |
KR20200022525A (en) * | 2008-12-04 | 2020-03-03 | 충시 위 | High Penetration Compositions and Their Applications |
CN108084246A (en) * | 2009-05-08 | 2018-05-29 | 上海泰飞尔生化技术有限公司 | The high penetrating power prodrugs composition of polypeptide and polypeptide related compound |
-
2010
- 2010-05-10 CN CN201710216624.0A patent/CN108084246A/en active Pending
- 2010-05-10 MX MX2011011876A patent/MX355995B/en active IP Right Grant
- 2010-05-10 ES ES10772043T patent/ES2845612T3/en active Active
- 2010-05-10 CN CN201810999280.XA patent/CN109232716A/en active Pending
- 2010-05-10 CN CN2010800309104A patent/CN102459313A/en active Pending
- 2010-05-10 TW TW099114877A patent/TWI568447B/en not_active IP Right Cessation
- 2010-05-10 DK DK10772043.5T patent/DK2427475T3/en active
- 2010-05-10 CA CA2761489A patent/CA2761489C/en active Active
- 2010-05-10 BR BRPI1011439A patent/BRPI1011439B8/en active IP Right Grant
- 2010-05-10 AU AU2010244857A patent/AU2010244857A1/en not_active Abandoned
- 2010-05-10 KR KR1020117029299A patent/KR101784528B1/en active IP Right Grant
- 2010-05-10 EP EP13170316.7A patent/EP2660247A3/en active Pending
- 2010-05-10 RU RU2011149796A patent/RU2627065C2/en not_active IP Right Cessation
- 2010-05-10 WO PCT/CN2010/072561 patent/WO2010127640A1/en active Application Filing
- 2010-05-10 PL PL10772043T patent/PL2427475T3/en unknown
- 2010-05-10 EP EP10772043.5A patent/EP2427475B1/en active Active
- 2010-05-10 KR KR1020187027764A patent/KR20180110187A/en not_active Application Discontinuation
- 2010-05-10 JP JP2012508891A patent/JP6352587B2/en active Active
- 2010-05-10 RU RU2016139056A patent/RU2767051C2/en not_active Application Discontinuation
- 2010-05-10 EP EP20205564.6A patent/EP4067370A1/en active Pending
- 2010-05-10 KR KR1020177027288A patent/KR101903768B1/en active IP Right Grant
-
2011
- 2011-11-08 US US13/291,904 patent/US9248109B2/en active Active - Reinstated
- 2011-11-08 MX MX2018005737A patent/MX2018005737A/en unknown
-
2016
- 2016-10-20 AU AU2016247145A patent/AU2016247145A1/en not_active Abandoned
- 2016-10-31 JP JP2016213784A patent/JP2017036325A/en active Pending
-
2018
- 2018-08-08 JP JP2018149455A patent/JP7194530B2/en active Active
-
2020
- 2020-07-29 JP JP2020128370A patent/JP2020189847A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2011149796A (en) | HIGHER DEVELOPMENT MEDICINAL COMPOSITIONS BASED ON PEPTIDES AND RELATED COMPOUNDS PEPTIDES | |
RU2016139056A (en) | HIGHER DEVELOPMENT MEDICINAL COMPOSITIONS BASED ON PEPTIDES AND RELATED COMPOUNDS PEPTIDES | |
US9376381B2 (en) | High penetration prodrug compositions of peptides and peptide-related compounds | |
JP6177975B2 (en) | Polyethylene glycol-based adrenomedullin prodrug and use thereof | |
KR101781789B1 (en) | Polyheterocyclic compounds highly potent as hcv inhibitors | |
JP5229897B2 (en) | Fibroblast activation protein alpha inhibitor | |
EP0361365A1 (en) | Aminobenzoic and aminocyclohexane-carboylic acid compounds, compositions, and their method of use | |
EA009727B1 (en) | Hiv cleavable by cd26 | |
EP0667163B1 (en) | Powder for nasal administration of peptidic or proteinaceous drug | |
CN1391558A (en) | Substituted 1,3-diaryl-2-pyridine-2-yl-3-(pyridine-2-ylamino)-propanol derivatives, methods for their production, pharmaceutical compositions containing the same and their use | |
JP4023554B2 (en) | Derivatives of aminosulfonic acid, use of the derivatives in the synthesis of pseudopeptides, and production methods thereof | |
RU2022102808A (en) | HIGH PENETRATION PRODRUG COMPOSITIONS BASED ON PEPTIDES AND PEPTIDE RELATED COMPOUNDS | |
ES2649964T3 (en) | Aminostatin derivatives for the treatment of osteoarthritis | |
RU2007132264A (en) | MEDICINAL FORMS 1R, 2S-METOXAMINE, METHOD FOR PRODUCING SUCH MEDICINAL FORMS (OPTIONS), PHARMACEUTICAL COMPOSITION INCLUDING THEM, AND METHOD FOR TREATMENT OF URINARY MEMBERSHIP | |
US11976137B2 (en) | Compounds for use as apelin receptor antagonists | |
KR100965247B1 (en) | Novel arylsulfonylimidazolone derivatives and an anti-cancer pharmaceutical composition comprising the same | |
CN108047304A (en) | - 7 selective depressant of metalloproteinases and its preparation method and application | |
CN105440104A (en) | Transdermal administration system of polypeptide and related compounds |